Additionally, promoter hypermethylation of MGMT, encoding O6-methylguanine-DNA methyltransferase, is used as a biomarker of MGMT silencing, which correlates with reduced responsiveness to temozolomide in glioblastoma [37]. Here, MGMT is linked to glioblastoma.